In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019 | Zendy

James A. Karlowsky | Zendy; Meredith Hackel | Zendy; Miki Takemura | Zendy; Yoshinori Yamano | Zendy; Roger Echols | Zendy; Daniel F. Sahm | Zendy

Open Access

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019

Author(s) -

James A. Karlowsky,

Meredith Hackel,

Miki Takemura,

Yoshinori Yamano,

Roger Echols,

Daniel F. Sahm

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01990-21

Subject(s) - gram , microbiology and biotechnology , gram negative bacterial infections , biology , in vitro , cephalosporin , gram negative bacteria , bacteria , antibiotics , genetics , escherichia coli , gene

We reportin vitro susceptibility data from five consecutive annual SIDERO-WT surveillance studies (2014 to 2019) for cefiderocol and comparators tested against Gram-negative clinical isolates from North America and Europe. CLSI broth microdilution was used to determine MICs forEnterobacterales (n = 31,896),Pseudomonas aeruginosa (n = 7,700),Acinetobacter baumannii complex (n = 5,225),Stenotrophomonas maltophilia (n = 2,030), andBurkholderia cepacia complex (n = 425).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research